This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research article
Tumor infiltrated macrophage-the fighter defends against recurrence of stage Ⅱcolorectal cancer
Guo-Wang Yang
Beijing Hospital of Traditional Chinese Medicine, Capital Medical University
Corresponding Author
ORCiD: https://orcid.org/0000-0002-0799-3864
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background
Biomarkers which can robustly predict the recurrence of stage II colorectal cancer (CRC) have been urgent needed. Immune cells highly related to the recurrence and prognosis of CRC. However, whether the immune cells take part in the recurrence of stage II CRC has not known.
Methods
Explored the roles and possible mechanism of immune cells in the recurrence of stage II CRC by public databases.
Results
Tumor Immune Estimation Resource (TIMER) analysis indicated the macrophage infiltration level in stage II CRC: Significantly higher in the nonrecurrence group than that in the recurrence group; Significantly negative correlated with the recurrence-related hub gene transferrin (TF); Significantly positive correlated with the improved disease-free survival (DFS) and overall survival (OS). And macrophage infiltration related-gene recurrent model (GRM) (area under the curve (AUC) = 0.906) provide a better performance than the GRM established previously (AUC = 0.882) to predict the recurrence of stage II CRC. Gene Set Enrichment Analysis (GSEA) analysis indicated macrophage (M1) infiltrated in the tumor microenvironment (TME) defending against recurrence as a dynamic process: M1 was activated by receiving the stimulus signals (LPS/IFN- γ) which released by CRC cells, then infiltrating and recognizing the tumor to secrete IL-6 to directly or indirectly act on TF or create anti-tumor TME to kill tumor cells.
Conclusions
This study maybe provides a novel immunological perspective to explore the mechanism of recurrence and improve clinical practice performance in stage II CRC.
Keywords
colorectal cancer, macrophage, predict, recurrence
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 19 Aug, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This is a preprint. It has not completed peer review.
Research article
Tumor infiltrated macrophage-the fighter defends against recurrence of stage Ⅱcolorectal cancer
Guo-Wang Yang
Beijing Hospital of Traditional Chinese Medicine, Capital Medical University
Corresponding Author
ORCiD: https://orcid.org/0000-0002-0799-3864
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 19 Aug, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background
Biomarkers which can robustly predict the recurrence of stage II colorectal cancer (CRC) have been urgent needed. Immune cells highly related to the recurrence and prognosis of CRC. However, whether the immune cells take part in the recurrence of stage II CRC has not known.
Methods
Explored the roles and possible mechanism of immune cells in the recurrence of stage II CRC by public databases.
Results
Tumor Immune Estimation Resource (TIMER) analysis indicated the macrophage infiltration level in stage II CRC: Significantly higher in the nonrecurrence group than that in the recurrence group; Significantly negative correlated with the recurrence-related hub gene transferrin (TF); Significantly positive correlated with the improved disease-free survival (DFS) and overall survival (OS). And macrophage infiltration related-gene recurrent model (GRM) (area under the curve (AUC) = 0.906) provide a better performance than the GRM established previously (AUC = 0.882) to predict the recurrence of stage II CRC. Gene Set Enrichment Analysis (GSEA) analysis indicated macrophage (M1) infiltrated in the tumor microenvironment (TME) defending against recurrence as a dynamic process: M1 was activated by receiving the stimulus signals (LPS/IFN- γ) which released by CRC cells, then infiltrating and recognizing the tumor to secrete IL-6 to directly or indirectly act on TF or create anti-tumor TME to kill tumor cells.
Conclusions
This study maybe provides a novel immunological perspective to explore the mechanism of recurrence and improve clinical practice performance in stage II CRC.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6